| P50 | author | Giuliano Tocci | Q37829220 |
| | Massimo Volpe | Q37829227 |
| P2093 | author name string | Giuseppe Villa | |
| | Carmine De Matteis | |
| | Tommaso Di Napoli | |
| | Antonino Granatelli | |
| | Armando Magagna | |
| | Dario Caputo | |
| | Alfonso A Matarrese | |
| | Davide Perona | |
| | DRIVE Investigators | |
| | Gianpiero Aimo | |
| | Pietro Lentini | |
| P2860 | cites work | Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: | Q22242896 |
| | Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction | Q22242900 |
| | Primary prevention of ischemic stroke | Q22306369 |
| | Definition and Evaluation of Transient Ischemic Attack | Q22337014 |
| | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| | Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis | Q28280366 |
| | Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes | Q28306261 |
| | Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. | Q31117595 |
| | Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A | Q33989952 |
| | Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry | Q34155229 |
| | Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials | Q34276433 |
| | Hypertension treatment and control in five European countries, Canada, and the United States | Q34279075 |
| | Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 |
| | 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension | Q34673532 |
| | Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials | Q34778622 |
| | Aliskiren: a review of its use in the management of hypertension | Q36903748 |
| | Aliskiren, the future of renin-angiotensin system blockade? | Q36941829 |
| | Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities | Q37939271 |
| | Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies | Q43143679 |
| | Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial | Q43208657 |
| | A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients | Q44221258 |
| | Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design | Q46162422 |
| | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 |
| | Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 |
| | Italian society of hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours | Q47323288 |
| | Blood pressure is insufficiently controlled in European patients with established coronary heart disease | Q47607268 |
| | Shattuck Lecture. The hypertension paradox--more uncontrolled disease despite improved therapy | Q48547775 |
| | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 |
| | Essential hypertension | Q57085592 |
| | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | Q57245141 |
| | Use of aliskiren in a ‘real-life’ model of hypertension management | Q61866086 |
| | Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults | Q63258542 |
| | Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials | Q81897757 |
| | Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study) | Q82876639 |
| P433 | issue | 2 | |
| P921 | main subject | Italy | Q38 |
| P304 | page(s) | 73-83 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | High Blood Pressure & Cardiovascular Prevention | Q24031395 |
| P1476 | title | An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy | |
| P478 | volume | 19 | |